Improving the role of immune checkpoint inhibitors in the management of advanced urothelial carcinoma, where do we stand?

被引：2

作者：

Houssiau, Helene ^{[1
]}

Seront, Emmanuel ^{[1
]}

机构：

[1] Ctr Hosp Jolimont, Dept Med Oncol, Rue Ferrer 159, B-7100 Haine Saint Paul, Belgium

来源：

TRANSLATIONAL ONCOLOGY | 2022年 / 19卷

关键词：

Urothelial carcinoma; Immune checkpoint inhibitors; Maintenance strategy; PD-L1; Platinum-based strategy; CISPLATIN-INELIGIBLE PATIENTS; INVASIVE BLADDER-CANCER; PHASE-II TRIAL; SINGLE-ARM; SUPPORTIVE CARE; OPEN-LABEL; CHEMOTHERAPY; MULTICENTER; ATEZOLIZUMAB; PLUS;

D O I：

10.1016/j.tranon.2022.101387

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Immune checkpoint inhibitors (ICIs) have significantly improved the outcome of patients with metastatic umthelial cancer (mUC). If these agents were first used in monotherapy after failure of platinum-based chemotherapy, new strategies have been evaluated in the last years, including association of ICIs, ICI plus chemotherapy association or maintenance therapy. This maintenance concept allows a better management of mUC, which is particularly interesting in cisplatin-ineligible patients. This paper aims to review the current knowledge of ICIs in urothelial carcinoma as well as the new indications of these agents in mUC.

引用

页数：11

共 50 条

[1] The Evolution of Immune Checkpoint Inhibitors in Advanced Urothelial Carcinoma
Houssiau, Helene
Seront, Emmanuel
CANCERS, 2022, 14 (07)
[2] Focus on Biochemical and Clinical Predictors of Response to Immune Checkpoint Inhibitors in Metastatic Urothelial Carcinoma: Where Do We Stand?
Roviello, Giandomenico
Catalano, Martina
Nobili, Stefania
Santi, Raffaella
Mini, Enrico
Nesi, Gabriella
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2020, 21 (21) : 1 - 14
[3] Immune checkpoint inhibitors for urothelial carcinoma
Kim, Hyung Suk
Seo, Ho Kyung
INVESTIGATIVE AND CLINICAL UROLOGY, 2018, 59 (05) : 285 - 296
[4] Treatment Rechallenge With Immune Checkpoint Inhibitors in Advanced Urothelial Carcinoma
Makrakis, Dimitrios
Bakaloudi, Dimitra Rafailia
Talukder, Rafee
Lin, Genevieve Ihsiu
Diamantopoulos, Leonidas N.
Jindal, Tanya
Vather-Wu, Naomi
Zakharia, Yousef
Tripathi, Nishita
Agarwal, Neeraj
Dawsey, Scott
Gupta, Shilpa
Lu, Eric
Drakaki, Alexandra
Liu, Sandy
Zakopoulou, Roubini
Bamias, Aristotelis
Fulgenzi, Claudia -Maria
Cortellini, Alessio
Pinato, David
Barata, Pedro
Grivas, Petros
Khaki, Ali Raza
Koshkin, Vadim S.
CLINICAL GENITOURINARY CANCER, 2023, 21 (02) : 286 - 294
[5] Urothelial carcinoma in the era of immune checkpoint inhibitors
Khalife, Nadine
Chahine, Claude
Kordahi, Manal
Felefly, Tony
Kourie, Hampig Raphael
Saleh, Khalil
IMMUNOTHERAPY, 2021, 13 (11) : 953 - 964
[6] A Review of Immune Checkpoint Inhibitors for the Management of Locally Advanced or Metastatic Urothelial Carcinoma
Hanna, Kirollos S.
PHARMACOTHERAPY, 2017, 37 (11): : 1391 - 1405
[7] Immune checkpoint inhibitors in ovarian cancer: where do we stand?
Leary, Alexandra
Tan, David
Ledermann, Jonathan
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2021, 13
[8] Systematic review of neoadjuvant therapy by immune checkpoint inhibitors before radical cystectomy: where do we stand?
Albisinni, Simone
Aoun, Fouad
Diamand, Romain
Mjaess, Georges
Esperto, Francesco
Martinez Chanza, Nieves
Roumeguere, Thierry
De Nunzio, Cosimo
MINERVA UROLOGICA E NEFROLOGICA, 2020, 72 (06) : 663 - 672
[9] Recent advances in immune checkpoint inhibitors in the treatment of urothelial carcinoma: A review
Kato, Minoru
Uchida, Junji
INTERNATIONAL JOURNAL OF UROLOGY, 2023, 30 (12) : 1068 - 1077
[10] Immune-checkpoint inhibitors in previously treated patients with advanced or metastatic urothelial carcinoma: A systematic review and meta-analysis
Di Nunno, Vincenzo
De Luca, Emmanuele
Buttigliero, Consuelo
Tucci, Marcello
Vignani, Francesca
Gatto, Lidia
Zichi, Clizia
Ardizzoni, Andrea
Di Maio, Massimo
Massari, Francesco
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2018, 129 : 124 - 132

← 1 2 3 4 5 →